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Human cytomegalovirus (HCMV) is a herpes virus that can cause severe infections. Still, 28 
the available methods for its diagnostic have the main disadvantage of requiring long 29 
time to be performed. In this work, a simple magnetic particle-based enzyme 30 
immunoassay (mpEIA) for the quantification of glycoprotein B of Human 31 
cytomegalovirus (gB-HCMV) in urine samples is proposed. The immunosensor scheme 32 
is based on the analyte protein gB-HCMV sandwiched between a primary monoclonal 33 
antibody, (MBs-PrG-mAb1), and a secondary anti-gB-HCMV antibody labelled with 34 
Horseradish peroxidase (Ab2-HRP) to allow spectrophotometric detection.  35 
The mpEIA analytical performance was tested in urine samples, showing a linear 36 
dependence between gB-HCMV concentration and the absorbance signal at 450 nm in 37 
a range of concentrations from 90 to 700 pg mL-1. The calculated detection limits for gB-38 
HCMV were 90±2 pg mL-1 and the RSD was about 6.7% in urine samples. The 39 
immunosensor showed good selectivity against other viruses from Herpesviridae family, 40 
namely varicella zoster and Epstein Barr viruses. The recoveries of spiked human urine 41 
samples at 0.30-0.50 ng mL-1 concentration levels of gB-HCMV ranged between 91 to 42 
105%. The proposed mpEIA method was validated following the guidelines of the 43 
European Medicines Agency (EMEA-2014), and allows rapid, successful and easy 44 
quantification of gB-HCMV in urine samples. 45 
 46 
 47 
1. Introduction 48 
Human cytomegalovirus (HCMV) is one of the eight herpesviruses that commonly infect 49 
humans, being its transmission facilitated by mucous contact [1,2]. It is recognized as 50 
the most common congenital viral infection in human and an important cause of 51 
morbidity and mortality in immunocompromised hosts [3]. Primary infection by HCMV 52 
results in the establishment of a lifelong latent infection, and its reactivation may occur 53 
in situations of immune system dysfunction or low maturity, resulting in severe clinical 54 
symptoms [1,2, 4, 5]. Still, the diagnosis of HCMV remains controversial because of the 55 
difficulty in separating patients who are asymptomatic (but carry HCMV) from patients who have 56 
the symptomatic disease [1]. The standard for diagnosis of HCMV infection are serological tests 57 
based on IgM and IgG detection [6]. IgG detection is only valuable for establishing past infection, 58 
or confirming seroconversion, while IgM has poor sensitivity and specificity to detect a recent 59 
infection. These tests usually require a minimum of two days [3]. On the other hand, the 60 
traditional method for direct free HCMV detection is viral isolation, that detect viral antigens in 61 
tissue, urine or saliva samples. Nevertheless, time analysis requirements for this method (≈ 20 62 
days) makes it disadvantageous to be routinely used in clinical diagnosis as point of care [5,78].  63 
As an alternative, the use of capture antibodies against the envelope glycoproteins of 64 
HCMV open the possibility of faster immunochemical methods of analysis. Glycoprotein 65 
B of HCMV (gB-HCMV) is a viral glycoprotein that plays a crucial role in virus entry into 66 
the cell and emerges during the early stages of a HCMV infection [8]. In addition, gG-67 
HCMV is the dominant antigen in the envelope of HCMV, being possible its 68 
determination in body fluids like urine, where viral loads are higher [9]. This is quite 69 
advantageous since the collection of these biological samples is simple and is performed 70 
by noninvasive procedures. In consequence, the development of new methods for the 71 
accurate detection of gB-HCMV in body fluids is of great interest, unlike the up 72 
mentioned analytical method based on the determination of antibodies generated by 73 
the HCMV virus [5]. 74 
Enzyme-linked immunosorbent assays (ELISA) have also great presence in clinical 75 
diagnostic tests [10]. However,  conventional ELISAs have some limitations, such as high 76 
costs (e.g. high quantities of antibodies immobilized on the wells of the microtiter wells), 77 
slow kinetics, and nonspecific adsorptions of conjugates and/or matrix interferers on 78 
the microplate wells [10]. Much of these limitations have been greatly improved with 79 
the recent use of surface-functionalized magnetic micro-beads (MBs), in the so-called 80 
magnetic particle-based enzyme immunoassays (mpEIA) [10]. The use of MBs improves 81 
the affinity interaction thanks to a faster assay kinetics of the dispersed beads. The 82 
surface area is higher than a flat solid phase of the wells (in a classical microtiter plate), 83 
and the washing and separation efficiencies are enhanced by using an external well-84 
controlled magnetic field, allowing the analysis of complex samples without any pre-85 
enrichment or purification steps [10, 11].  86 
Thus, in this work, we propose a spectrophotometric mpEIA method for the rapid and 87 
simple gB-HCMV determination in urine samples (see the immunoassay scheme of Fig. 88 
1). Magnetic particles functionalized with protein G (MBs-prG), allows the antibody 89 
(mAb1) oriented immobilization, resulting in a more effective recognition of gB-HCMV 90 
[12]. The spectrophotometric detection  was performed through a secondary antibody 91 
labelled with Horseradish peroxidase (Ab2-HRP)[5,8,10]. Special attention was given to 92 
the non-specific adsorptions (NSA) of gB-HCMV and Ab2-HRP, as they have a very 93 
negative influence in quantitative immunoassays [13]. After optimization of the 94 
experimental conditions, the validation of the mpEIA method was carried out according 95 
to the “Guideline on bioanalytical method validation”, from the European Medicines 96 
Agency (EMEA) (2014) [14]. The developed immunosensor was shown to be a fast and 97 
effective method for gB-HCMV quantification in human urine samples for the useful 98 
determination of HCMV infections. 99 
 100 
 101 
2. Material and methods  102 
2.1.  Apparatus 103 
Spectrophotometric measurements were made with a Bio-Rad model 680 Microplate 104 
Absorbance Spectrophotometer (Bio-Rad, Hercules, CA, USA). Standard 96-well 105 
polystyrene microplates (ref. 82.1581) were supplied from Sarstedt (Nümbrecht, 106 
Germany). A magnetic 96-well separator (ThermoFisher Scientific, Waltham, MA, USA) 107 
was used to separate the MBs from the supernatants to make easier the removal of 108 
solvent from the standard ELISA plates. Incubation process was carried out using Grant 109 
Bio POS-300 Orbital Shaking Platform (Cambridge, UK). A magnetic separation stand for 110 
eppendorf vials (Z5342, 12 positions, 1.5 mL volume) was purchased from Promega 111 
(Madison, WI, USA).  112 
 113 
2.2.  Reagents 114 
Human cytomegalovirus glycoprotein B (gB-HCMV) and Anti-Cytomegalovirus 115 
glycoprotein B primary and secondary antibodies (mAb1 and Ab2-HRP) were purchased 116 
from Abcam (ab43040, ab69245, ab6499, respectively) (Cambridge, UK). Bovine serum 117 
albumin (BSA), peroxidase substrate 3,3’,5,5’-tetramethylbenzidine liquid substrate 118 
system for ELISA (TMB), Tween-20 and monosodium phosphate were obtained from 119 
Sigma-Aldrich (Madrid, Spain). Disodium phosphate and sulfuric acid were acquired 120 
from Panreac (Barcelona, Spain). Sodium chloride was purchased from Fisher Scientific 121 
(Bishop’s Stortford, UK) and dynabeads® protein G immunoprecipitation kit and Pierce 122 
Protein-Free were products from Thermofisher Scientific. Urine samples were obtained 123 
from healthy volunteers after informed consent. All the reagents used were of analytical 124 
grade and Milli Q water Millipore (Burlington, MA, USA) was used for preparing all 125 
solutions. 126 
 127 
2.3.  Primary antibody immobilization on functionalized magnetic beads 128 
Dynabeads® were re-suspended in the vial (vortexed >30 sec or tilted and rotated for 5 129 
min). Then, 50 µL (1.5 mg) of MBs-PrG Dynabeads® were transfer to a tube, washed 130 
three times with 500 µL of PBS buffer in order to remove NaN3 preservative and the 131 
surfactant. Each washing step consisted on the re-suspension of the beads in PBS buffer, 132 
followed by supernatant clearance under a magnetic field that retain the beads and 133 
separate them from solution. 134 
After MBs-PrG cleaning, the desired amount of primary antibody (mAb1), diluted in PBS, 135 
was added to them and left to incubate for 10 min at room temperature. The antibody 136 
modified MBs (MB-PrG-mAb1) were washed three times with PBS buffer, reconstituted 137 
in PBS (1.0 mL), and stored at 4 ºC when not in use. According to the manufacturer, it is 138 
not recommended to freeze (−20 °C) these kind of MBs.  139 
 140 
2.4.  Immunoassay determination of gB-HCMV 141 
All the immunoassay incubations were made on standard polystyrene flat-bottom 142 
microtest plates coupled with a magnetic support with 96x individual magnets to hold 143 
back the modified MBs on each of the microplate wells. In order to avoid nonspecific 144 
adsorption, the wells of the microplate were, firstly, blocked overnight by using the 145 
commercial solution Pierce Protein-Free. Following emptying of the wells, 25 µL of MBs-146 
mAb1 (containing 5 µg of MBs) were added to each well and the remaining sites of the 147 
beads surface blocked with BSA 4% during 60 minutes at room temperature. After this, 148 
25 µL of gB-HCMV standard (or the clinical sample) were added to obtain a final 149 
concentration over the range from 0 to 800 pg mL-1 gB-HCMV. Incubations were carried 150 
out for 60 minutes at room temperature with gentle orbital agitation. Finally, 25 µL of 151 
the Ab2-HRP was added to each well and left to incubate for 60 minutes at room 152 
temperature with gentle orbital agitation.  153 
Between each of the incubation steps, the wells were washed three times with 300 µL 154 
of PBS and the solvent removed under an external magnetic field for retaining the 155 
modified MBs. For the mpEIA spectrophotometric measurements of Ab2-HRP, 50 µL of 156 
the peroxidase substrate TMB reagent was added to each well, left to react for 10 min 157 
at room temperature, stopped with 0.5 M H2SO4 and the absorbance measured at 450 158 
nm with an ELISA reader.  159 
 160 
3. Results and Discussion 161 
As it is well known, immunoassays are greatly dependent on experimental conditions, 162 
being imperative their detailed optimization for achieving the best analytical properties. 163 
A sandwich assay scheme was used for the construction of our immunosensor, as it 164 
improves selectivity against a competitive immunoassay scheme, once two selected 165 
antibodies are used for the specific recognition of different parts of the same gB-HCMV 166 
protein. After incubation with the primary antibody, a HRP-labeled secondary antibody 167 
(Ab2-HRP) was used to generate the analytical signal for gB-HCMV detection. The 168 
scheme of this mpEIA immunosensor assay is shown in Fig. 1.  169 
Special attention was paid to avoid NSA of the gB-HCMV protein and the Ab2-HRP 170 
conjugated antibody, both on the wall of the microtiter wells and on the modified 171 
surface of MBs-PrG-mAb1, since this would falsify the analytical signals, not due to the 172 
extension of the incubation reactions. It was also considered the possibility of unwanted 173 
interactions between primary and secondary antibodies [15].  174 
After optimizations, the mpEIA analytical performance in quantifying gB-HCMV was 175 
tested. In order to evaluate the feasibility of the proposed assay for real samples 176 
analysis, the mpEIA was used for the determination of gB-HCMV in human urine 177 
samples, and cross-reactivity evaluated with Epstein-Barr virus (EBV) and Varicela-zoster 178 
(VZV) antigens, both viruses from the Herpesviridae family. 179 
 180 
3.1 Optimization of the experimental conditions 181 
It is well known that NSA can occur on the surface of the 96 well polystyrene ELISA plate 182 
through physical adsorption by electrostatic and/or van der Waals forces and/or by 183 
hydrophobic interactions [16]. In order to avoid NSA of the biological reagents on the 184 
wells, three blocking agents were tested, namely the SuperBlock and Pierce Protein-Free 185 
commercial solutions and a 4% bovine serum albumin (BSA) solution prepared in 0.1 PBS 186 
(pH=7.4). After blocking the wells overnight with these solutions, incubations of the 187 
secondary Ab2-HRP antibody were carried out (25 µL for 60 min.), and the absorbances 188 
measured after reaction with TMB, as explained in section 2.4. The results are shown in 189 
Fig. 2. As it can be seen, in presence of SuperBlock no difference is observed compared 190 
to when no blockage is performed, demonstrating secondary antibody nonspecific 191 
adsorption to the well’s walls and the inefficiency of this blocking agent. The lowest 192 
absorbance values were obtained with 4% BSA and Pierce Protein-Free solutions. 193 
Despite the similarity between their absorbance mean values (0.175 and 0.180 194 
respectively), Pierce Protein-Free solution was chosen as the optimal blocking agent, 195 
once the relative standard deviations obtained in replicated tests were of 17.3% for 196 
Pierce Protein-Free and 27.4% for BSA blocking solutions.  197 
 Although hydrophobic interactions play an essential role in epitope-antibody binding, 198 
these forces may also promote nonspecific interactions between primary and secondary 199 
antibodies. Low levels of a detergent, such as Tween-20, are known to reduce surface 200 
tension and as consequence this type of interaction [17]. Accordingly, in order to further 201 
lower the background signal, a PBS + 0.02% Tween-20 solution was used during the 202 
secondary antibody incubation step. No changes of the absorbances were observed 203 
using tween-20 solutions, showing that hydrophobic interactions do not significantly 204 
contribute to the global NSA. 205 
With the use of MBs modified with capture antibody in the immunosensor scheme, a 206 
high background signal was observed after incubations with Ab2-HRP (without gB-207 
HCMV), indicating nonspecific adsorptions of the conjugated Ab2-HRP antibody on the 208 
unblocked MBs surface. Thus, the MBs blockage was considered to avoid this problem 209 
[18]. Two blocking agents (BSA and Pierce Protein-Free) were evaluated. The lower 210 
absorbance signals due to NSA of Ab2-HRP were obtained with 4% and 5% of BSA 211 
solutions, as it is shown in Fig. 3. However, a decrease in gB-HCMV detection 212 
absorbances were found with more than 5% of BSA solutions, suggesting that BSA blocks 213 
some antigen binding sites of the mAb1 antibody, reducing the ability to detect gB-214 
HCMV. The best concentration for this purpose was 4% BSA, once it shows lower blank 215 
signals and it did not interfere with the gB-HCMV antigen detection. Experimental 216 
conditions strongly influence the sensitivity of the sandwich immunoassays. In 217 
particular, it is important that the number of available binding sites of the primary 218 
(mAb1) and secondary (Ab2-HRP) antibodies be in excess of the stoichiometric amount 219 
of the gB-HCMV analyte. Under these conditions, adequate absorbance values are 220 
produced (Absorbance ≤ 1.0) according to Fig. 4 a linear range of concentrations from 221 
70 pg mL-1 to 800 pg mL-1 was obtained. 222 
 223 
3.2 Immunosensor analytical performance 224 
The analytical performance of the immunoassay was evaluated following the guidelines 225 
of the European Medicines Agency on bioanalytical method validation [14]. Accordingly, 226 
the main characteristics that are essential to ensure the acceptability of a bioanalytic 227 
method are: calibration curve performance, lower limit of quantification, matrix effect, 228 
precision, selectivity and accuracy. 229 
Calibration standards were prepared measured in PBS buffer and urine matrices for 230 
comparison purposes. Urine was chosen to evaluate the immunosensor performance, 231 
once high virus load is found in excreted urine from HCMV infected individuals [9]. In 232 
presence of PBS buffer, absorbance at 450 nm increased linearly with analyte 233 
concentration in the narrow range from 70 pg mL-1 to 800 pg mL-1, showing the 234 
calibration curve a good linear correlation coefficient (Table 1). Higher concentrations 235 
produced saturation of the binding sites of primary antibody. Although this range of 236 
concentrations quantification is small, it provides clinically useful and sensitive 237 
information for the control of HCMV, once the appropriate dilution of the samples have 238 
been carried out. 239 
To test the biological matrix effect on the magnetic particles based immunoassay, gB-240 
HCMV standards were prepared in a 2-fold diluted urine sample from healthy patients 241 
in PBS buffer pH 7.4. Replicated calibration graphs were carried out in PBS 0.1 M. buffer 242 
and in diluted urine samples.  The linear range in presence of urine (between 90 pg mL-243 
1 to 700 pg mL-1 of gB-HCMV) was slightly smaller than that observed in PBS buffer, 244 
possibly due to the presence of other matrix components in the urine samples, that 245 
might block some antigen binding sites of the primary mAb1, leading to an earlier 246 
saturation. Nevertheless, there was not significant differences between the slopes of 247 
both calibrating graphs in the two matrices (95% level of confidence). In both calibration 248 
curves, three replicates for each gB-HCMV concentration were performed and the RSD 249 
exhibits an average value of 13.7% when PBS matrix is used and 6.25% in urine samples. 250 
These RSD values are acceptable for this kind of immunosensors and the very low 251 
concentrations of gB-HCMV measured, at the pg mL-1 order [19]. 252 
The lowest detection (LOD) and quantification (LOQ) limits are one of the most 253 
important properties in applying immunosensors to clinical samples and to obtain the 254 
least number of false negatives. The first stage in LOD calculation was the determination 255 
of a linear relation between gB-HCMV concentration and absorbance signal at 450 nm 256 
(Table 1). Anomalous points were avoided using least median squares regression (LMS) 257 
[20,21]. Then, in order to check the LOD values, results from the calibration curves were 258 
evaluated by using the DETARCHI software [22], that calculates detection limits with an 259 
evaluation of the probability of false positive (α) and negative (β), according to 260 
ISO11843-2, 2000 [23]. A limit of detection of 70±10 pg mL-1 for gB-HCMV in buffer and 261 
90±20 pg mL-1 for gB-HCMV in urine samples were obtained for α=β=0.05. These two 262 
values are very similar, reinforcing the non-existence of interferences from the matrix 263 
in the immunosensor response.  264 
To our knowledge, very few immunosensors for the direct determination of gB-HCMV 265 
have been reported. A piezoelectric affinity sensor has been proposed, which is based 266 
on the immobilization of anti gB-HCMV antibodies on gold electrodes [24]. The 267 
sensitivity of this immunosensor is, however, very low (LOD about 1 µg mL-1 of gB-268 
HCMV), owing to the intrinsic low sensitivity of this analytical technique.  269 
We have also previously reported an electrochemical immunosensor for gB-HCMV 270 
detection, by using capture anti-gB-HCMV antibodies absorbed on screen-printed 271 
carbon electrodes, and secondary anti-gB-HCMV antibodies labelled with gold 272 
nanoparticles [5]. gB-HCMV detection was carried out through electrochemical stripping 273 
analysis of silver nanoparticles deposited quantitatively on the immunosensor, 274 
catalyzed by the nanogold labels [5]. However, the reproducibility of this method (RSDs 275 
of about 12%) was not very good owing to the random immobilization of the primary 276 
antibody on the working electrode, which resulted in small efficiency of antigen 277 
detection, low signals compared to the large amount of this antibody used, and the 278 
nonspecific deposition of silver on the sensor surface in this kind of voltammetric 279 
detection [25].  280 
In this way, the results obtained with the proposed mpEIA compares favorably to those 281 
obtained in other reports of gB-HCMV detection shown in Table 2, in terms of analytical 282 
performance. Of all the methods for the detection of gB, the proposed method is the 283 
one that presents lowers limits of detection with shorter sample preparation times (the 284 
only need to prepare the urine samples are dilutions with 0.10 M. PBS buffer).  285 
The proposed immunochemical method must discriminate the gB-HCMV analyte of 286 
interest from other related viruses in the studied biological samples. The presented 287 
approach might have the possibility of false positive results, caused by cross-reactions 288 
with some virus of Herpesviridae family, once they are morphologically and structurally 289 
related [1,28]. To evaluate the selectivity of the antibody, one virus from each sub-family 290 
of Herpesviridae family was selected as possible interfere, namely the Epstein-Barr (EBV) 291 
and Varicela-zoster (VZV) viruses. In order to evaluate cross reactivities, concentrations 292 
of 300, 400 and 500 pg mL-1 of the above virus antigens were assayed, and the gB-HCMV 293 
concentration was measured following the proposed method. The obtained 294 
absorbances were compared with a control assay, which consisted in a blank test, i.e. 295 
PBS buffer was added instead of the analyte to the immunassay. A false positive was 296 
considered when the assay with these viruses produced higher spectrophotometric 297 
signals compared to the control assay. According to the results, given in Fig. 5, all the 298 
assays with EBV and VZV antigens showed lower signals than the control, meaning that 299 
the secondary Ab-HRP did not bind during the assays. In contrast, all the tests with gB-300 
HCMV showed higher signals, demonstrating the primary and secondary antibody 301 
specificities to gB-HCMV with the sandwich immunoassay scheme.  302 
In order to evaluate the analytical applicability of the proposed mpEIA method, urine 303 
samples, collected from a healthy human, were spiked with 300, 400 and 500 pg mL-1 of 304 
gB-HCMV and analyzed immediately. The absorbances of the spiked samples, following 305 
the mpEIA procedure (section 2.4), were measured and were interpolated in the 306 
calibration curve obtained with urine. The results are shown in Table 3. The 307 
measurements of each sample were replicated (n=5), and the results of the Table are 308 
the mean±SD. 309 
The precision of the mpEIA assay was estimated based on repeat measurements of 310 
standard diluted urine samples with spiked concentrations of gB-HCMV (Table 3). The 311 
relative standard deviations have acceptable values, lesser than about 8.1% in all cases 312 
(n=5), in accordance with the usually obtained for these types of immunosensors based 313 
on magnetic particles compared with classical ELISAs [10]. The relative errors at these 314 
very low levels of gB-HCMV concentrations are also smaller than about 4.7% in all cases, 315 
demonstrating the successful applicability of the method in urine biological matrices. 316 
It should also be noted the high sensitivity of the developed mpEIA method, being able 317 
to detect gB-HCMV concentrations of few pg mL-1, and a limit of detection of 90 pg mL-318 
1 of gB-HCMV, much smaller than others reported for the same analyte (Table 2). For 319 
example, as it was reported in our previous work with a disposable electrochemical 320 
sandwich immunosensor, the limit of detection was 3.2±0.2 ng mL-1 for the same 321 
glycoprotein [5]. 322 
The overall analysis time of samples with the proposed immunosensor is shorter when 323 
compared to the usually applied methods of HCMV virus isolation, DNA amplification, 324 
or antibody screening [1]. ≈24 h  using techniques such as antibody detection and shell-325 
vial and ≈6 h for polymerase chain reaction. The mpEIA can analyze a sample within ≈3 326 
h, a little more compared with our previous work (≈1h) owing to the incubations time 327 
needed in this sandwich assay, but with a lower limit of detection and better sensitivity, 328 
accuracy, and reproducibility (Table 2). 329 
Despite, the most common target analyte used for HCMV quantification being virus 330 
DNA, is important to emphasize that our method targets the structural protein, gB-331 
HCMV, present on the HCMV virus envelope. HCMV is released in urine, during active 332 
infection, and our method will allow the infection identification for a minimal 333 
concentration of 90±20 pg mL-1 gB-HCMV in this specific body fluid. We expect that the 334 
viral load will be directly proportional to gB-HCMV concentration. Ongoing work is being 335 
developed to establish the correlation between gB-HCMV concentration and viral load, 336 
which will be of great interest to monitor patient response to therapy. 337 
4. Conclusions 338 
A sensitive mpEIA is proposed for the rapid (about 3 h) determination of gB-HMCV 339 
protein in urine samples, with the objective of early screening and quick diagnostics of 340 
HCMV infections. Magnetic beads functionalized with PrG allow the oriented 341 
immobilization of the primary mAb1 antibody by its Fc part, which has more affinity and 342 
efficiency to bind to the antigen protein. Incubations in a dispersed mode, due to the 343 
magnetic beads, improve kinetics and also the washing and separating steps of the 344 
immunoassay compared with a classical ELISA in which the detecting antibodies are 345 
immobilized on the solid surface of the wells of a microtiter plate.  346 
The sandwich immunoassay scheme improves selectivity over other human herpes 347 
viruses, given that gB-HCMV is recognized through two epitopes by both capture and 348 
secondary antibodies. The secondary antibody labeled with HRP provides a convenient 349 
way to simply obtain the spectrophotometric signals. 350 
The developed method was partially validated following the recommendations of the 351 
EMEA, and allows the determination of gB-HCMV in urine samples at a relevant range 352 
of concentrations from 90 to 700 ng mL-1 of gB-HCMV. 353 
The calculated detection limit in urine samples was 90±20 pg mL-1. Reproducibility 354 
exhibits an average RSD value of 6.25 %. Spiked of human urine samples at pg mL-1 levels 355 
provided relative errors lower than approximately 4.7%, demonstrating a very good 356 
accuracy. The presence of other similar herpes viruses (varicella zoster and Epstein Barr) 357 
does not interfere. 358 
ELISA readers are frequently available in biochemical laboratories, but additionally, this 359 
same mpEIA method can be easily adapted to electrochemical transduction on screen-360 
printed electrodes. Multiplexed electrochemical transduction of mpEIA provides 361 
simplicity, sensitivity and portability of the instrument, as we have previously 362 
demonstrated with competitive assay schemes in the determination of drugs of abuse 363 
and mycotoxins in foods [29].  364 
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Table 1.
Slope R2 Linear concentration range, ng mL-1
Detection limit, 
ng mL-1
PBS 0.97 ± 0.02 0.996 0.10 –0.80 0.07 ± 0.01
Urine 1.17 ± 0.04 0.993 0.10 – 0.70 0.09 ±0.02
Table 2.
Method Biological matrix Analyte
Concentration 
range Limit of detection 
Overall analysis 
time Reference








--- gB-HCMV 2.5 -5 µg mL-1 1 µg mL-1 ~20h [13]
Electrochemical 
immunosensor Urine gB-HCMV 5-15 ng mL
-1 3.2 ± 0.2 ng mL-1 ~1h [4]
Electrochemical 
Immunoassay Saliva pp65 0.1 – 80 ng mL
-1 30 pg mL-1 >24h [34]





concentration, ng mL-1 % Recovery RSD %
0.30 0.28±0.01 93.3% 4.7%
0.40 0.41±0.03 102.5% 6.5%
0.50 0.53±0.01 106.0& 4.5%
